Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Setmelanotide

Shows how peptide therapeutics can be tied to molecular diagnosis and highly selected patient populations rather than broad wellness use.

Conceptual three-dimensional molecular signature for Setmelanotide; not an exact chemical structure.
MC4 receptor agonist peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved for genetically defined obesity indications

MHRA / UK LICENCE

UK authorised for defined genetic obesity indications

NICE STATUS

NICE highly specialised recommendations exist for defined populations

NHS ACCESS

Highly specialised NHS access exists within NICE criteria

PRIVATE LAWFUL USE CONTEXT

Lawful use is indication specific and specialist led

EVIDENCE MATURITY

Authorised evidence in genetically defined obesity populations

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Specialist

PROFESSIONAL RELEVANCE

Track diagnostics, eligible population definitions, specialised commissioning and value assessment.

Product, formulation and indication

Imcivree

UK · Injection

Defined genetic obesity syndromes

Imcivree

US · Injection

Defined genetic obesity syndromes

Status history

Production baseline verification recorded.

FDA approved precision obesity medicine

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.